Your browser doesn't support javascript.
loading
Investigation of Caspase 9 Gene Polymorphism in Patients With Non-small Cell Lung Cancer.
Ercan, Sina; Arinc, Sibel; Yilmaz, Seda Gulec; Altunok, Cigdem; Yaman, Feride; Isbir, Turgay.
Afiliação
  • Ercan S; Department of Thoracic Surgery Faculty of Medicine, Yeditepe University, Istanbul, Turkey sercan@yeditepe.edu.tr.
  • Arinc S; Süreyyapasa Chest Disease and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey.
  • Yilmaz SG; Department of Molecular Medicine, Institute of Health Sciences, Yeditepe University, Istanbul, Turkey.
  • Altunok C; Department of Biostatistics and Medical Informatics, Faculty of Medicine, Yeditepe University, Istanbul, Turkey.
  • Yaman F; Süreyyapasa Chest Disease and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey.
  • Isbir T; Department of Medical Biology, Faculty of Medicine, Yeditepe University, Istanbul, Turkey.
Anticancer Res ; 39(5): 2437-2441, 2019 May.
Article em En | MEDLINE | ID: mdl-31092436
ABSTRACT
BACKGROUND/

AIM:

Non-small cell lung cancer (NSCLC) is one of the most common forms of lung cancer and the leading cause of cancer-related deaths in the world. Caspase 9 (CASP9) plays a central role in the intrinsic apoptotic pathway. The aim of the study was to investigate the role of caspase 9 gene polymorphism in patients with non-small cell lung cancer. MATERIALS AND

METHODS:

The study included 96 NSCLC cases and 67 controls. CASP9 Ex5+32 G>A polymorphism was investigated by real-time polymerase chain reaction.

RESULTS:

There was a significant difference between the groups in the frequency of CASP9 genotypes (p=0.008). The number of the carriers of the ancestral GG genotype, was significantly higher in the NSCLC group than in the control (p=0.009). The heterozygote GA genotype and mutant A allele frequency were significantly higher in the control group compared to the NSCLC group (p=0.005, p=0.009, respectively). Serum CASP9 levels were significantly lower in the patients group than in the control group (p<0.0001).

CONCLUSION:

CASP9 Ex5+32 GG genotype was a risk factor whereas the variant A allele could be a risk-reducing factor for NSCLC.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Predisposição Genética para Doença / Caspase 9 / Estudos de Associação Genética Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Predisposição Genética para Doença / Caspase 9 / Estudos de Associação Genética Idioma: En Ano de publicação: 2019 Tipo de documento: Article